Short- and Long-term Efficacy and Safety of Levosimendan in Veno-arterial Extracorporeal Membrane Oxygenation Weaning: The WEANILEVO Randomized Double-blind Multicenter Trial
Primary resultResult — go to the resultOdds ratio 1.00 95% CI 0.36–2.75Authors' conclusion
Levosimendan administration did not reduce VA-ECMO weaning failure in patients who already met weaning criteria; however, a clinically important benefit or harm cannot be ruled out.
Study context
- Population
- Patients on veno-arterial extracorporeal membrane oxygenation (VA-ECMO) meeting weaning criteria, 5 French centresmodified ITT analysis
- Participants
- 80 patients
- Comparison
- Levosimendan vs placebo for 24 h
- Levosimendann = 40
- Placebon = 40reference
- Primary endpoint
- VA-ECMO weaning failure (no weaning within 48 h, another circulatory assistance device, or death within 7 days of weaning)
Methodological detailsmulticentre, double-blind, parallel-group, placebo-controlled, Planned sample size not reached
- Multicentre
- Double-blind
- Parallel-group
- Placebo-controlled
- Planned sample size not reached
Primary result
As reported in the abstract
Odds ratio
1.00
95% CI 0.36–2.75
P = 1.00
By group
Levosimendan vs Placebo
OR 1.00 (95% CI 0.36–2.75); P = 1.00
Further findings
Vasopressor support required
P = 0.07
| Outcome | P value |
|---|---|
| ICU LOS | P = 0.02 |
| Mortality · 30 days | P = 0.07 |
| Mortality · 1 yr | P = 0.08 |
Safety
| Outcome | Levosimendan | Placebo | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| AKI · day 30 | 62.5% | 38.5% | 2.67 (1.08–6.62) | P = 0.03 | |
| 0.10.31310Odds ratio (log scale) |
Original publication
Short- and Long-term Efficacy and Safety of Levosimendan in Veno-arterial Extracorporeal Membrane Oxygenation Weaning: The WEANILEVO Randomized Double-blind Multicenter Trial. Anesthesiology. Published 8 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →